 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma
|
|
|
|
Phase IV
|
|
|
|
U2963n
NCT00097565
|
|
| |
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
|
|
|
|
Phase III, Phase II
|
|
|
|
GC P#02.01.001
NCT00469729
|
|
| |
In-Vivo Activated T-Cell Depletion to Prevent GVHD
|
|
|
|
Phase III, Phase II
|
|
|
|
0705-20 IUCRO-0196
NCT00594308
|
|
| |
Non-Myeloablative Allogeneic HSCT From HLA Matched Related Donors for the Treatment of Low Grade B Cell Malignancies
|
|
|
|
Phase III, Phase II
|
|
|
|
F080429003
UAB-0775, NCT00714259
|
|
| |
Mobilization of Stem Cells with AMD3100 in Non-Hodgkin’s Lymphoma Patients
|
|
|
|
Phase III
|
|
|
|
AMD3100-3101
NCT00103610
|
|
| |
HuMax-CD20 in FL Patients Refractory to Rituximab
|
|
|
|
Phase III
|
|
|
|
Hx-CD20-405
NCT00394836
|
|
| |
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
|
|
|
|
Phase III
|
|
|
|
U4391g
NCT00719472
|
|
| |
Biological Therapy in Treating Patients With Lymphoma or Lymphoproliferative Disease
|
|
|
|
Phase II, Phase I
|
|
|
|
MSKCC-95024
NCI-V95-0685, NCT00002663
|
|
| |
Stem Cell Transplant for Hematologic Diseases and Renal Cell Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
H8713
NCT00058825
|
|
| |
Pentostatin and Donor White Blood Cells in Preventing Graft Rejection in Cancer Patients Who Have Undergone Donor Stem Cell Transplantation
|
|
|
|
Phase II, Phase I
|
|
|
|
FHCRC-1825.00
5605, SUPERGEN-FHCRC-1825.00, NCT00096161
|
|
